Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Food and Rabeprazole on Fruquintinib PK in Healthy Subjects
NCT04645940Phase 1Completed
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Sep 2020
- Primary completion
- Nov 2020
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fruquintinib in colorectal cancer (CRC) (2 arms), sponsored by Hutchison MediPharma (HMP). Primary endpoints: Area under the plasma-concentration time curve from time 0 to time of the last measurable concentration up to 36 days, Area under the plasma-concentration time curve from time 0 to infinity up to 36 days and 1 more. Started Sep 2020; status: completed.
02
Drugs
fruquintinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04645940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04645940.